tiprankstipranks
Trending News
More News >
Akari Therapeutics PLC (ADR) (AKTX)
:AKTX
US Market

Akari Therapeutics (AKTX) Income Statement

Compare
319 Followers

Akari Therapeutics Income Statement

Last quarter (Q3 2025), Akari Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Akari Therapeutics's net income was $-6.36M. See Akari Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 21.64M$ 16.81M$ 23.09M$ 17.21M$ 17.98M
Depreciation and Amortization
$ 14.00K$ 4.00K$ 4.00K$ 4.13K$ 8.91K
EBITDA
$ -19.53M$ -16.80M$ -23.08M$ -17.21M$ -17.97M
Operating Income
$ -21.64M$ -16.81M$ -23.09M$ -17.21M$ -17.98M
Other Income/Expenses
$ 1.85M$ 6.80M$ 5.34M$ -210.10K$ 899.36K
Pretax Income
$ -19.79M$ -10.01M$ -17.75M$ -17.42M$ -17.08M
Net Income
$ -19.79M$ -10.01M$ -17.75M$ -17.42M$ -17.08M
Per Share Metrics
Basic EPS
$ -1.66K$ -200.00$ -220.00$ -820.00$ -1.56K
Diluted EPS
$ -1.66K$ -200.00$ -220.00$ -820.00$ -1.12K
Weighted Average Shares Outstanding
11.94K 4.89K 3.12K 2.15K 1.12K
Weighted Average Shares Outstanding (Diluted)
11.94K 4.89K 3.12K 2.15K 1.58K
Currency in USD

Akari Therapeutics Earnings and Revenue History